Literature DB >> 2066802

Noninvasive method to obtain input function for measuring tissue glucose utilization of thoracic and abdominal organs.

T Ohtake1, N Kosaka, T Watanabe, I Yokoyama, T Moritan, M Masuo, M Iizuka, K Kozeni, T Momose, S Oku.   

Abstract

We have developed a method for the noninvasive estimation of regional tissue glucose utilization in humans that employs positron emission tomography (PET) and 2-(18F)fluoro-2-deoxy-d-glucose (FDG). Unlike other methods, the input function used in this method is obtained from the corrected time-activity curve of the descending aorta, not the left ventricle, because the descending aorta is relatively free of spillover from other organs and extends from the upper thorax to the lower abdomen. With this method the time-activity curve of the descending aorta must be corrected for the partial volume effect and the difference in counts between plasma and whole blood. Using the noninvasively obtained input function, regional tissue glucose utilization was calculated by Patlak graphic analysis. k1k3/(k2 + k3) was in good agreement with k1k3/(k2 + k3) calculated from the plasma input function by arterial sampling (r = 0.9995). These results suggest that the input function and regional tissue glucose utilization (not only of myocardium but also of other thoracic and abdominal organs) can be determined noninvasively.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2066802

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  45 in total

1.  Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis.

Authors:  Antonia Dimitrakopoulou-Strauss; Ludwig G Strauss; Gerlinde Egerer; Julie Vasamiliette; Thomas Schmitt; Uwe Haberkorn; Bernd Kasper
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-25       Impact factor: 9.236

2.  Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.

Authors:  Sophia Koukouraki; Ludwig G Strauss; Vassilios Georgoulias; Michael Eisenhut; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-09       Impact factor: 9.236

3.  Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.

Authors:  Sophia Koukouraki; Ludwig G Strauss; Vassilios Georgoulias; Jochen Schuhmacher; Uwe Haberkorn; Nikolaos Karkavitsas; Antonia Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-01-17       Impact factor: 9.236

4.  Image-derived input function for assessment of 18F-FDG uptake by the inflamed lung.

Authors:  Tobias Schroeder; Marcos F Vidal Melo; Guido Musch; R Scott Harris; Jose G Venegas; Tilo Winkler
Journal:  J Nucl Med       Date:  2007-10-17       Impact factor: 10.057

5.  Simple method to quantify myocardial glucose metabolism from MB ratio in myocardial FDG PET.

Authors:  J Nishikawa; T Ohtake; I Yokoyama; T Watanabe; T Momose; Y Sasaki
Journal:  Ann Nucl Med       Date:  1996-08       Impact factor: 2.668

6.  PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics.

Authors:  Christos Sachpekidis; Hartmut Goldschmidt; Dirk Hose; Leyun Pan; Caixia Cheng; Klaus Kopka; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

7.  68Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis.

Authors:  Christos Sachpekidis; Leyun Pan; Boris A Hadaschik; Klaus Kopka; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-10-20

8.  Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation.

Authors:  Christos Sachpekidis; J Hillengass; H Goldschmidt; B Wagner; U Haberkorn; K Kopka; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-29       Impact factor: 9.236

9.  Early effects of FOLFOX treatment of colorectal tumour in an animal model: assessment of changes in gene expression and FDG kinetics.

Authors:  Ludwig G Strauss; Johannes Hoffend; Dirk Koczan; Leyun Pan; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-11       Impact factor: 9.236

Review 10.  Methodological considerations in quantification of oncological FDG PET studies.

Authors:  Dennis Vriens; Eric P Visser; Lioe-Fee de Geus-Oei; Wim J G Oyen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-20       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.